Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 17Gastrointestinal 2Thoracic 1Plasma cell 1Head & Neck 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Glioblastoma 275Brain Neoplasms 169Glioma 139Central Nervous System Neoplasms 85Gliosarcoma 79Astrocytoma 74Neuroblastoma 64Oligodendroglioma 42Neoplasms 40Breast Neoplasms 38Recurrence 37Carcinoma, Non-Small-Cell Lung 30Medulloblastoma 27Melanoma 26Ovarian Neoplasms 24Lymphoma 21Diffuse Intrinsic Pontine Glioma 21Sarcoma 19Neoplasm Metastasis 19Lung Neoplasms 18Colorectal Neoplasms 17Rhabdomyosarcoma 16Osteosarcoma 16Meningeal Carcinomatosis 15Pancreatic Neoplasms 14Meningioma 14Ependymoma 14Sarcoma, Ewing 13Stomach Neoplasms 12Esophageal Neoplasms 12

Interventions

silmitasertib 1Vincristine 1Temozolomide 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Liposarcoma × CNS × Clear all
NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
104 enrolled
CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡